CymaBay Therapeutics Inc. [NASDAQ: CBAY] closed the trading session at $1.56 on 02/12/20. The day’s price range saw the stock hit a low of $1.48, while the highest price level was $1.58. The stocks have a year to date performance of -20.41 percent and weekly performance of -1.89 percent. The stock has been moved at -73.78 percent over the last six months. The stock has performed -17.46 percent around the most recent 30 days and changed -72.24 percent over the most recent 3-months.

If compared to the average trading volume of 2.31M shares, CBAY reached to a volume of 4811170 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about CymaBay Therapeutics Inc. [CBAY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CBAY shares is $2.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CBAY stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for CymaBay Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 26, 2019. The new note on the price target was released on November 26, 2019, representing the official price target for CymaBay Therapeutics Inc. stock. Previously, the target price had yet another drop from $16 to $2, while H.C. Wainwright kept a Neutral rating on CBAY stock. On November 26, 2019, analysts decreased their price target for CBAY shares from 20 to 2.

The Average True Range (ATR) for CymaBay Therapeutics Inc. is set at 0.10 The Price to Book ratio for the last quarter was 0.50, with the Price to Cash per share for the same quarter was set at 3.12.

CBAY stock trade performance evaluation

CymaBay Therapeutics Inc. [CBAY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.89. With this latest performance, CBAY shares dropped by -17.46% in over the last four-week period, additionally sinking by -73.78% over the last 6 months – not to mention a drop of -83.54% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CBAY stock in for the last two-week period is set at 37.02, with the RSI for the last a single of trading hit 30.99, and the three-weeks RSI is set at 33.14 for CymaBay Therapeutics Inc. [CBAY]. The present Moving Average for the last 50 days of trading for this stock 1.81, while it was recorded at 1.56 for the last single week of trading, and 5.68 for the last 200 days.

CymaBay Therapeutics Inc. [CBAY]: An insightful look at the core fundamentals

Return on Total Capital for CBAY is now -55.46, given the latest momentum, and Return on Invested Capital for the company is -56.16. Return on Equity for this stock declined to -56.82, with Return on Assets sitting at -49.86.

Reflecting on the efficiency of the workforce at the company, CymaBay Therapeutics Inc. [CBAY] managed to generate an average of -$1,687,163 per employee.CymaBay Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.10 and a Current Ratio set at 13.10.

Earnings per share (EPS) analysis for CymaBay Therapeutics Inc. [CBAY] stock

With the latest financial reports released by the company, CymaBay Therapeutics Inc. posted -0.32/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CBAY.

CymaBay Therapeutics Inc. [CBAY]: Insider Ownership positions

There are presently around $91 million, in the hands of institutional investors. The top three institutional holders of CBAY stocks are: BAKER BROS. ADVISORS LP with ownership of 5,707,411, which is approximately 0% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 5,628,239 shares of the stock with an approximate value of $8.72 million in CBAY stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $5.77 million in CBAY stock with ownership of nearly 24.817% of the company’s market capitalization.

Positions in CymaBay Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 58 institutional holders increased their position in CymaBay Therapeutics Inc. [NASDAQ:CBAY] by around 4,930,041 shares. Additionally, 63 investors decreased positions by around 15,130,545 shares, while 38 investors held positions by with 38,485,662 shares. The mentioned changes placed institutional holdings at 58,546,248 shares, according to the latest SEC report filing. CBAY stock had 21 new institutional investments in for a total of 1,651,536 shares, while 28 institutional investors sold positions of 8,131,657 shares during the same period.